Head and Neck Neoplasms Clinical Trial
Official title:
New Introducer PEG-Gastropexy Does Not Need Prophylactic Antibiotics: Prospective Randomised Double Blind Placebo Controlled Trial
Peristomal infections are the commonest complications of PEG despite prophylactic antibiotics which may result in emergence of resistant micro-organisms like Methicillin resistant Staphylococcus aureus (MRSA). Introducer PEG technique avoids the sojourn of PEG catheter through the oropharynx so chances of infectious complications are negligible. It was not popular because of associated risks and complications. However the new introducer PEG gastropexy has been recently proved to be safe. To determine the incidence of peristomal wound infections during the immediate 7 day post procedure follow up period after the new introducer PEG gastropexy
BACKGROUND:PEG can be performed by pull, push or introducer technique, pull method is the
one most commonly used worldwide. PEG site infection is clearly the commonest procedure
related complication of PEG placement and the routinely used pull technique has been shown
to have quite high (4-30%), peristomal infectious complications. To curtail these infectious
complications various gastroenterological societies have recommended giving intravenous
prophylactic antibiotics 30 minutes prior to the procedure which has been shown to
significantly reduce this complication. Despite this the incidence of peristomal infectious
complications remains high post PEG. Another problem associated with the administration of
prophylactic antibiotics is the emergence of resistant micro-organisms especially the
Methicillin resistant Staphylococcus aureus (MRSA) at the PEG site. Introducer PEG is the
technique of PEG placement which avoids the transit of PEG catheter through the oropharynx.
Despite its introduction since 19 years back it has not become popular among endoscopists
because of technical difficulties and complications associated with it. However the newer
introducer PEG technique using endoscopic gastropexy has been shown to be quite safe and
easy to perform in recent studies. We at our institute have been performing this procedure
since January 2003 and on prospective follow up have found much lower incidence of
peristomal infections with it. Recently Maetani et al have already demonstrated in a
prospective randomised trial that the introducer type PEG results in fewer infectious
complications as compared to conventional pull PEG. There is no study comparing introducer
PEG technique with or without administration of prophylactic antibiotics. As in principal,
the chances of infections are much lower in the introducer technique. We want to address
this issue in a randomised double blind placebo controlled settings in those patients who
will as it is unfit to undergo routine pull PEG because of upper gastrointestinal (UGI)
malignant stenoses.
SUMMARY: Peristomal infections are the commonest complications of PEG despite prophylactic
antibiotics which may result in emergence of resistant micro-organisms like Methicillin
resistant Staphylococcus aureus (MRSA). Introducer PEG technique avoids the travel of PEG
catheter through the oropharynx which is richly inhabitated with microorganisms so chances
of infectious complications at the raw PEG wound are negligible. This technique was not
popular because of associated risks and complications in the past which has shown it to
result in complications like deflation of balloons, catheter dislodgement, leading to
peritonitis etc. However the new introducer PEG gastropexy has been recently proved to be
safe. At our institute about 200 PEG procedures are performed annually, out of these 10-12%
have tight stenotic stricture in which pull PEG is not possible without dilatation of
oropharyngeal tract. We plan to randomise these patients in to 2 groups with and without
antibiotics (placebo). PEG will be done using the new introducer PEG, Freka® Pexact CH/FR 15
(Fresenius Kabi, Germany), in which the gastric wall is sutured non surgically to the
anterior abdominal wall using 2 silk sutures. Peristomal wound would be assessed daily for 7
days using 2 types of point scores systems (given by Jain and by Gossner) by 2 members of
nutrition support team independently. As these are the objective scoring systems, we intend
to determine the grades of post procedure peristomal infections in these patients.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05980598 -
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02548377 -
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Not yet recruiting |
NCT06347185 -
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
|
N/A | |
Terminated |
NCT02975739 -
Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors
|
N/A | |
Recruiting |
NCT00982436 -
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01025518 -
DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients
|
N/A | |
Active, not recruiting |
NCT00248235 -
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00135161 -
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
|
Phase 1 | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Not yet recruiting |
NCT06458517 -
Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers
|
N/A | |
Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT03286972 -
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
|
||
Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT03975465 -
EMST and Swallowing in Long-Term Survivors of HNCA
|
N/A | |
Recruiting |
NCT03678649 -
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
|
Phase 2 | |
Completed |
NCT03292250 -
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
|
Phase 2 | |
Completed |
NCT06446570 -
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
|
Phase 2 |